2025
Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes
How J, Leiva O, Redd R, Marneth A, DeAngelo D, Dieli-Conwright C, El-Jawahri A, Kamaz B, Kim C, Lindsley C, Luskin M, Stahl M, Wazir M, Weeks L, Hobbs G. Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes. Blood Vessels Thrombosis & Hemostasis 2025, 100051. DOI: 10.1016/j.bvth.2025.100051.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsCardiovascular risk factorsEssential thrombocythemiaMyeloproliferative neoplasmsPolycythemia veraThrombotic outcomesThrombotic riskRisk factorsDiagnosis of hematological malignanciesMyeloproliferative neoplasm subtypeIncreased risk of deathType 2 diabetes mellitusMyeloproliferative neoplasms diagnosisRetrospective cohort analysisSex-matched controlsManaging cardiovascular risk factorsAssociated with survivalImprove patient morbidityRisk of deathMF patientsHematologic malignanciesMPN diagnosisPatient morbidityDana-FarberArterial/venous thrombosis
2024
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions
Bidikian A, Bewersdorf J, Shallis R, Getz T, Stempel J, Kewan T, Stahl M, Zeidan A. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. Expert Review Of Anticancer Therapy 2024, 24: 1131-1146. PMID: 39367718, DOI: 10.1080/14737140.2024.2414071.Peer-Reviewed Original ResearchErythropoiesis-stimulating agentsTargeted therapyLR-MDSHR-MDSHypoxia-inducible factorAllogeneic hematopoietic stem cell transplantationLandscape of targeted therapiesHematopoietic stem cell transplantationHeterogeneous group of hematologic malignanciesGroup of hematologic malignanciesMolecular prognostic toolsDuration of responseStem cell transplantationTrial designClinical trial designHypomethylating agentsCell transplantationHematologic malignanciesImprove patient outcomesRNA splicing machineryImmune evasionPrognostic toolTGF-betaTherapyEffective treatmentAcute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome
Alhajahjeh A, Bewersdorf J, Bystrom R, Zeidan A, Shimony S, Stahl M. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leukemia & Lymphoma 2024, 65: 1541-1551. PMID: 38962996, DOI: 10.1080/10428194.2024.2367040.Peer-Reviewed Original ResearchAcute myeloid leukemiaIntensive chemotherapyHypomethylating agentsMyeloid leukemiaAllogeneic stem cell transplantationAcute myeloid leukemia casesAcute myeloid leukemia subtypesStem cell transplantationComplex hematological malignancyCurrent treatment modalitiesRare genetic anomalyCell transplantationHematologic malignanciesTreatment modalitiesClinical outcomesTreatment responseInv(3Genetic alterationsLeukemia developmentTreatment strategiesCellular processesGenetic anomaliesLeukemiaFusion geneClinical implications
2021
Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub
Desai P, Goldberg A, Anderson K, Narendra V, Neuberg D, Radhakrishnan V, Redd R, Roboz G, Sehn L, Sekeres M, Stahl M, Tallman M, Thompson J, Tucker E, Wood W, Hicks L. Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub. Blood 2021, 138: 280. PMCID: PMC8701680, DOI: 10.1182/blood-2021-146016.Peer-Reviewed Original ResearchAcute myeloid leukemiaAcute lymphocytic leukemiaEntity's Board of DirectorsMyelodysplastic syndromeTime of COVID-19 diagnosisCurrent equity holderActive diseaseBoard of directorsCOVID-19 severityCOVID-19 infectionCOVID-19 registryICU careCOVID-19 diagnosisHematologic malignanciesBristol Myers SquibbPublicly-traded companiesResponse groupMultivariate analysisPredictors of severe infectionTypes of hematological malignanciesHospitalized patientsAssociated with advanced ageAssociated with neutropeniaAssociated with increased mortalitySevere COVID-19 infectionRisks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology
Hicks L, Redd R, Anderson K, Desai P, Dolan B, Goldberg A, Narendra V, Neuberg D, Radhakrishnan V, Sehn L, Sekeres M, Stahl M, Tallman M, Thompson J, Tucker E, Wood W. Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology. Blood 2021, 138: 3040. PMCID: PMC8701544, DOI: 10.1182/blood-2021-154283.Peer-Reviewed Original ResearchEntity's Board of DirectorsTypes of hematological malignanciesPlasma cell dyscrasiaHematologic malignanciesCOVID-19 mortalityMultivariate logistic regressionGrand roundsCOVID-19 registryMale sexCancer treatmentIncreased riskMultivariate analysisICU carePre-COVID-19Blood disordersBristol Myers SquibbCOVID-19 infectionImpact of cancer treatmentLogistic regressionAdvisory CommitteeResearch fundingRisk of COVID-19 mortalityIncreased risk of COVID-19 mortalityMedian age categoryOutcomes of COVID-19 infectionNeutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality
Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer M, Mato A, Roeker L, Tallman M, Shah G, Daniyan A, Goldberg A. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia & Lymphoma 2021, 62: 1940-1948. PMID: 34180767, PMCID: PMC10080398, DOI: 10.1080/10428194.2021.1885664.Peer-Reviewed Original ResearchConceptsAdult acute myeloid leukemia patientsAcute myeloid leukemia patientsMemorial Sloan Kettering Cancer CenterCourse of COVID-19 infectionAssociated with increased odds of deathDiagnosis of AMLClinical course of COVID-19 infectionMyeloid leukemia patientsFlow nasal cannulaAssociated with increased oddsOdds of deathClinical courseHematologic malignanciesChronic leukemiaNasal cannulaLeukemia patientsCOVID-19 infectionMechanical ventilationPoor outcomeCancer CenterActive treatmentLeukemia subtypesRelated mortalityPatientsRisk factors
2020
Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia
Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. Current Cancer Drug Targets 2020, 20: 473-489. PMID: 32357813, DOI: 10.2174/1568009620666200502011059.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsAntibodies, MonoclonalAntigens, NeoplasmAntineoplastic Agents, ImmunologicalCancer VaccinesHematopoietic Stem Cell TransplantationHumansImmunotherapy, AdoptiveKiller Cells, NaturalLeukemia, Myeloid, AcuteReceptors, Chimeric AntigenT-Lymphocytes, CytotoxicTransplantation, HomologousTumor EscapeConceptsAcute myeloid leukemiaTumor-associated antigensImmune systemAML cellsMyeloid leukemiaTreatment of AMLAllogeneic stem cell transplantationEffective immunotherapeutic strategiesNatural killer cellsStem cell transplantationHumoral immune reactionsCell-based therapeutic approachesSurface receptor expressionAcute leukemia cellsDirect immunosuppressionImmunotherapeutic strategiesTreatment landscapeImmunotherapeutic approachesCellular immunotherapyKiller cellsCell transplantationClinical managementHematologic malignanciesReceptor expressionDecreased immunogenicity
2019
Getting personal with myelodysplastic syndromes: is now the right time?
Chokr N, Pine AB, Bewersdorf JP, Shallis RM, Stahl M, Zeidan AM. Getting personal with myelodysplastic syndromes: is now the right time? Expert Review Of Hematology 2019, 12: 215-224. PMID: 30977414, PMCID: PMC6540985, DOI: 10.1080/17474086.2019.1592673.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeNext-generation sequencingTherapy selectionPrognosis of MDSRole of NGSPrognosis of patientsRoutine clinical practiceMinimal residual diseaseRecurrent genetic abnormalitiesResidual diseaseBlood countDisease stagePeripheral bloodHematologic malignanciesPrognostic evaluationMDS pathogenesisRoutine managementTherapy decisionsHealthy individualsBone marrowClinical practiceCytological examinationPatientsScoring systemDiagnostic accuracy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply